Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Apr;37(2):91-105.
doi: 10.4093/dmj.2013.37.2.91.

Cell therapy for diabetic neuropathy using adult stem or progenitor cells

Ji Woong Han  1 , Min Young Sin, Young-Sup Yoon
Affiliations

Cell therapy for diabetic neuropathy using adult stem or progenitor cells

Ji Woong Han et al. Diabetes Metab J. 2013 Apr.

Abstract

Diabetic neuropathy (DN) is the most common and disabling complication of diabetes that may lead to foot ulcers and limb amputations. Despite widespread awareness of DN, the only effective treatments are glucose control and pain management. A growing body of evidence suggests that DN is characterized by reduction of vascularity in peripheral nerves and deficiency in neurotrophic and angiogenic factors. Previous studies have tried to introduce neurotrophic or angiogenic factors in the form of protein or gene for therapy, but the effect was not significant. Recent studies have shown that bone marrow (BM)-derived stem or progenitor cells have favorable effects on the repair of cardiovascular diseases. Since these BM-derived stem or progenitor cells contain various angiogenic and neurotrophic factors, these cells have been attempted for treating experimental DN, and turned out to be effective for reversing various manifestations of experimental DN. These evidences suggest that cell therapy, affecting both vascular and neural components, can represent a novel therapeutic option for treatment of clinical DN.

Keywords: Diabetic neuropathies; Stem cells; Tissue therapy.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1
Fig. 1
Pathogenesis of diabetic neuropathy (DN). Metabolic interactions vascular factors are involved at all stages of DN. Hyperglycemia, dyslipidemia, metabolic syndrome, impaired insulin signaling, and growth factor deficiency are correlated with the occurrence of neuropathy. Reduced blood flow through loss of autonomic nerve functions may contribute to the progression of DN, and alterations in microvessels, similar to the pathogenic neovascularization described in diabetic retinopathy and nephropathy, also are observed in peripheral nerves.
Fig. 2
Fig. 2
Cell therapy for diabetic neuropathy (DN) using adult stem or progenitor cells. Candidate adult stem or progenitor cells include mononuclear cells (MNCs), endothelial progenitor cells (EPCs), or mesenchymal stem cells (MSCs) from cord blood (CB)-, bone marrow (BM)-, or peripheral blood (PB)-derived cells. Through angiogenic and neurotrophic effects, these cells can reverse various functional and histologic manifestations of DN.
See this image and copyright information in PMC

References

    1. Verrotti A, Loiacono G, Mohn A, Chiarelli F. New insights in diabetic autonomic neuropathy in children and adolescents. Eur J Endocrinol. 2009;161:811–818. - PubMed
    1. Apfel SC. Neurotrophic factors and pain. Clin J Pain. 2000;16(2 Suppl):S7–S11. - PubMed
    1. Lupachyk S, Shevalye H, Maksimchyk Y, Drel VR, Obrosova IG. PARP inhibition alleviates diabetes-induced systemic oxidative stress and neural tissue 4-hydroxynonenal adduct accumulation: correlation with peripheral nerve function. Free Radic Biol Med. 2011;50:1400–1409. - PMC - PubMed
    1. Vincent AM, Callaghan BC, Smith AL, Feldman EL. Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat Rev Neurol. 2011;7:573–583. - PubMed
    1. Leinninger GM, Vincent AM, Feldman EL. The role of growth factors in diabetic peripheral neuropathy. J Peripher Nerv Syst. 2004;9:26–53. - PubMed